Moderna said on May 17 that the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing Covid-19 vaccine dispute with Pfizer and BioNTech.
Moderna said Friday that the European Patent Office has upheld the validity of one of its key patents, a victory in a continuing dispute with Pfizer and BioNTech over rival COVID-19 vaccines.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved ...
London: Moderna has won a case at the European Patent Office against Pfizer and BioNTech in a dispute over its COVID-19 vaccine, the company said on Friday. The vaccine maker has been locked in an ...
Moderna MRNA-Q said on Friday the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer PFE-N and BioNTech ...